Unknown

Dataset Information

0

Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells.


ABSTRACT: Glioblastoma Multiforme (GBM) is a highly prevalent and deadly brain malignancy characterized by poor prognosis and restricted disease management potential. Despite the success of nanocarrier systems to improve drug/gene therapy for cancer, active targeting specificity remains a major hurdle for GBM. Additionally, since the brain is a multi-cell type organ, there is a critical need to develop an approach to distinguish between GBM cells and healthy brain cells for safe and successful treatment. In this report, we have incorporated hyaluronic acid (HA) as an active targeting ligand for GBM. To do so, we employed HA conjugated liposomes (HALNPs) to study the uptake pathway in key cells in the brain including primary astrocytes, microglia, and human GBM cells. We observed that the HALNPs specifically target GBM cells over other brain cells due to higher expression of CD44 in tumor cells. Furthermore, CD44 driven HALNP uptake into GBM cells resulted in lysosomal evasion and increased efficacy of Doxorubicin, a model anti-neoplastic agent, while the astrocytes and microglia cells exhibited extensive HALNP-lysosome co-localization and decreased antineoplastic potency. In summary, novel CD44 targeted lipid based nanocarriers appear to be proficient in mediating site-specific delivery of drugs via CD44 receptors in GBM cells, with an improved therapeutic margin and safety.

SUBMITTER: Hayward SL 

PROVIDER: S-EPMC5085145 | biostudies-other | 2016 Jun

REPOSITORIES: biostudies-other

altmetric image

Publications

Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells.

Hayward Stephen L SL   Wilson Christina L CL   Kidambi Srivatsan S  

Oncotarget 20160601 23


Glioblastoma Multiforme (GBM) is a highly prevalent and deadly brain malignancy characterized by poor prognosis and restricted disease management potential. Despite the success of nanocarrier systems to improve drug/gene therapy for cancer, active targeting specificity remains a major hurdle for GBM. Additionally, since the brain is a multi-cell type organ, there is a critical need to develop an approach to distinguish between GBM cells and healthy brain cells for safe and successful treatment.  ...[more]

Similar Datasets

| S-EPMC6121415 | biostudies-literature
| S-EPMC7490593 | biostudies-literature
| S-EPMC9877355 | biostudies-literature
| S-EPMC9287456 | biostudies-literature
| S-EPMC3638880 | biostudies-literature
| S-EPMC4430437 | biostudies-literature
| S-EPMC4649614 | biostudies-literature
| S-EPMC7213297 | biostudies-literature
| S-EPMC5498804 | biostudies-other
| S-EPMC5318300 | biostudies-literature